[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"upper-urinary-tract-carcinoma\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:upper-urinary-tract-carcinoma":33},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,59],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":42,"overallStatus":46,"whyStopped":4,"lastUpdateSubmitDate":47,"lastUpdatePostDateStruct":48,"startDateStruct":51,"completionDateStruct":53,"leadSponsor":55,"locationsCount":58},"100400786","stereotactic-body-radiotherapy-in-patients-with-rare-oligometastatic-cancers-oligorare-100400786",false,"NCT04498767","Stereotactic Body Radiotherapy in Patients With Rare Oligometastatic Cancers (OligoRARE)","Stereotactic Body Radiotherapy in Addition to Standard of Care Treatment in Patients With Rare Oligometastatic Cancers (OligoRARE): a Randomized, Phase 3, Open-label Trial","OligoRARE","Inclusion Criteria:\n\n* Histologically confirmed malignancy with metastatic disease detected on imaging. Biopsy of metastasis is preferred, but not required.\n* Controlled primary tumour, defined as:\n* at least 3 months since original tumour treated definitively, with no progression at primary site\n* Total number of oligometastases of 1-5 including:\n* Brain metastases amenable to radiosurgery or fractionated stereotactic radiotherapy patient who had neurosurgical resection before trial inclusion are allowed and resected brain metastases count to the total number of oligometastases\n* All sites of disease can be safely treated based on the judgement of an experienced radiation oncologist\n* ECOG score 0-2\n* Life expectancy \\> 6 months\n* Age 18 or older\n* Before patient randomization, written informed consent must be given according to ICH\u002FGCP, and national\u002Flocal regulations.\n\nExclusion Criteria:\n\n* Primary cancer of prostate, breast, lung or colorectal\n* Serious medical comorbidities precluding radiotherapy:\n* These include interstitial lung disease in patients requiring thoracic radiation, Crohn's disease in patients where the GI tract will receive radiotherapy, or ulcerative colitis where the bowel will receive radiotherapy and connective tissue disorders such as lupus or scleroderma.\n* For patients with liver metastases, moderate\u002Fsevere liver dysfunction (Child Pugh B or C)\n* Substantial overlap with a previously treated radiation volume. Prior radiotherapy in general is allowed, as long as the composite plan meets dose constraints herein. For patients treated previously with radiation, biological effective dose calculations should be used to equate previous doses to the tolerance doses listed in the RTQA Guidelines. All such cases should be discussed with one of the study coordinators\n* Brain metastases only, without extra-cerebral metastases\n* Malignant pleural effusion, malignant ascites, meningeal carcinomatosis and peritoneal carcinomatosis\n* Maximum size of 6 cm for lesions outside the brain, except:\n* Bone metastases over 5 cm may be included, if in the opinion of the local radiation oncologist it can be treated safely (e.g. rib, scapula, pelvis)\n* Clinical or radiologic evidence of symptomatic spinal cord compression. Patients can be eligible if surgical resection has been performed, but the surgical site counts toward the total of up to 3 metastases.\n* Metastatic disease that invades any of the following: GI tract (including oesophagus, stomach, small or large bowel), mesenteric lymph nodes, or disseminated skin metastases and lymphangiosis\n* Pregnant or breast feeding women\n* Any psychological, familial, sociological or geographical condition potentially hampering compliance with the study protocol and follow-up schedule; those conditions should be discussed with the patient before randomization in the trial","ALL","18 Years",{"count":20,"type":21},200,"ESTIMATED","INTERVENTIONAL",[24],"NA","This is a randomized open-label multicentre Phase III superiority study of the effect of adding SBRT to the standard of care treatment on overall survival in patients with rare oligometastatic cancers.\n\nPatients will be randomized in a 1:1 ratio between current standard of care treatment vs. standard of care treatment + SBRT to all sites of known metastatic disease.\n\nThe primary objective of this trial is to assess if the addition of stereotactic body radiotherapy (SBRT) to standard of care treatment improves overall survival (OS) as compared to standard of care treatment alone in patients with rare oligometastatic cancers.",[27,28,29,30,31,32,33,34,35,36,37,38,39,40,41],"Gynecologic Cancer","Skin Cancer","Head and Neck Cancer","Sarcoma","Renal Cancer","Bladder Cancer","Upper Urinary Tract Carcinoma","Pancreatic Cancer","Hepatobiliary Cancer","Gastric Cancer","Small Bowel Cancer","Esophageal Cancer","Melanoma","Colon Cancer","Oligometastasis",[43,44,45],"oligometastatic cancer","Stereotactic body radiotherapy","SBRT","RECRUITING","2024-08-23",{"date":49,"type":50},"2024-08-26","ACTUAL",{"date":52,"type":50},"2021-06-10",{"date":54,"type":21},"2030-02-01",{"name":56,"class":57},"European Organisation for Research and Treatment of Cancer - EORTC","NETWORK",13,{"id":60,"slug":61,"hasResults":11,"nctId":62,"briefTitle":63,"officialTitle":64,"acronym":65,"eligibilityCriteria":66,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":67,"targetDuration":69,"studyType":70,"phases":4,"briefSummary":71,"conditions":72,"keywords":73,"overallStatus":46,"whyStopped":4,"lastUpdateSubmitDate":77,"lastUpdatePostDateStruct":78,"startDateStruct":80,"completionDateStruct":82,"leadSponsor":84,"locationsCount":87},"100495471","effect-of-a-si-mmc-on-the-ivr-rate-after-ureteroscopy-for-utuc-100495471","NCT05731622","Effect of a SI-MMC on the IVR Rate After Ureteroscopy for UTUC","Effect of a Single Instillation of Mitomycin C on the Intravesical Recurrence Rate After Ureteroscopy for Upper Tract Urothelial Carcinoma: A Prospective, Multicenter Study","SINCERE","Inclusion Criteria:\n\n* All patients suspect for having non-metastatic disease and planned for ureteroscopy (diagnostic or treatment) and adjuvant single instillation of Mitomycin C\n* Age ≥18 years\n* Written informed consent\n\nExclusion Criteria:\n\n* History of histological proven urothelial carcinoma of the bladder, including carcinoma in situ\n* History of histological proven UTUC in the contralateral kidney\n* Concurrent bladder tumour found pre-operatively or per-operatively\n* Patients where it is not feasible to obtain histology by biopsies intra-operatively\n* Known Mitomycin C\n* Renal transplantation",{"count":68,"type":21},100,"2 Years","OBSERVATIONAL","The goal of this observational study is to evaluate the intravesical recurrence (IVR) rate after ureteroscopy (diagnostic or treatment) for upper tract urothelial carcinoma (UTUC) followed by an adjuvant single instillation of Mitomycin C (SI-MMC).\n\nThe main question it aims to answer are:\n\n* What is the total and time to IVR after 2 years after ureteroscopy (diagnostic or treatment) for UTUC\n* How is the IVR compared with a historical cohort (no SI-MMC)\n* What is the time to IVR after 2 years in patients who subsequently received treatment by endoscopy vs. radical nephroureterectomy (RNU)\n* What is the additional value of a SI-MMC on time to IVR after RNU + adjuvant MMC in patients who were evaluated by ureteroscopy prior to RNU",[33],[74,75,76],"Intravesical recurrence","Mitomycin C","Ureteroscopy","2024-01-30",{"date":79,"type":50},"2024-01-31",{"date":81,"type":21},"2024-02",{"date":83,"type":21},"2026-09",{"name":85,"class":86},"Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)","OTHER",1]